DexCom, Inc. (NASDAQ:DXCM) Receives $97.42 Average PT from Brokerages

Shares of DexCom, Inc. (NASDAQ:DXCM) have been given a consensus recommendation of “Moderate Buy” by the twenty-three analysts that are presently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have issued a strong buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $97.4211.

A number of research firms have recently commented on DXCM. UBS Group boosted their target price on shares of DexCom from $105.00 to $106.00 and gave the stock a “buy” rating in a research note on Thursday, July 31st. Weiss Ratings reiterated a “hold (c-)” rating on shares of DexCom in a research note on Wednesday, October 8th. William Blair upgraded DexCom to a “strong-buy” rating in a research note on Thursday, July 31st. Robert W. Baird dropped their price target on DexCom from $112.00 to $90.00 and set an “outperform” rating for the company in a research report on Friday, September 26th. Finally, Piper Sandler boosted their price target on DexCom from $90.00 to $100.00 and gave the stock an “overweight” rating in a research report on Thursday, July 31st.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 1,466 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the sale, the executive vice president directly owned 105,223 shares in the company, valued at $8,417,840. This represents a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Kyle Malady sold 667 shares of the company’s stock in a transaction on Friday, September 5th. The shares were sold at an average price of $80.86, for a total value of $53,933.62. Following the completion of the sale, the director owned 22,667 shares of the company’s stock, valued at approximately $1,832,853.62. The trade was a 2.86% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,849 shares of company stock worth $564,733 in the last 90 days. 0.32% of the stock is currently owned by insiders.

Institutional Trading of DexCom

Several large investors have recently added to or reduced their stakes in the stock. Andra AP fonden purchased a new stake in shares of DexCom in the second quarter valued at about $26,000. Twin Peaks Wealth Advisors LLC purchased a new stake in shares of DexCom in the second quarter valued at about $26,000. Golden State Wealth Management LLC grew its stake in shares of DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock valued at $27,000 after buying an additional 264 shares during the period. Zions Bancorporation National Association UT purchased a new stake in shares of DexCom in the 1st quarter valued at approximately $27,000. Finally, Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of DexCom in the 2nd quarter valued at approximately $45,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Price Performance

Shares of DexCom stock opened at $66.21 on Friday. The firm has a market cap of $25.96 billion, a PE ratio of 45.98, a P/E/G ratio of 1.37 and a beta of 1.47. DexCom has a twelve month low of $57.52 and a twelve month high of $93.25. The business has a 50-day moving average price of $74.01 and a 200 day moving average price of $77.62. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.45 by $0.03. The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm’s revenue was up 15.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. Sell-side analysts predict that DexCom will post 2.03 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.